|
Company Profile
Pulmotect, Inc. is a Houston-based biotechnology company,
developing products that boost the innate immune system to
protect against a wide range of lung infections. Our
cofounders are leaders in the emerging science of innate
immunity in the lungs. Our technologies stimulate the body’s
natural defenses to provide safe, broad-spectrum,
fast-acting protection against bacterial pneumonia
(including MRSA), influenza, fungal pneumonia, and Class A
bioterror agents (including anthrax, tularemia, and the
plague).
Three major markets exist for
this technology:
-
Immunocompromised patients:
Initial focus is centered on high-risk leukemia
patients, where physicians are eager to conduct clinical
trials. Additional immunocompromised patients include
ICU, elderly, HIV and other cancer patients.
-
Treating and preventing
pneumonia: Current methods to treat the flu are
inadequate. By locally stimulating the innate immune
system in the respiratory system, the flu could be
better prevented and treated. Additional government
concerns deal with pandemic threats.
-
Bioterror uses: First responders,
military personnel and the US population could benefit
from locally stimulating the immune system providing
protection in seconds instead of weeks.
Funding
The technology has been awarded
~$2.5 million of non-dilutive funding to date.
-
AlphaDev partnership (first
dilutive funding)
-
Awarded $250,000 from the Texas Emerging Technology Fund, with an additional $750,000 set aside
-
Inaugural Texas Ignition
Fund award, $10,000
-
U.T. M. D. Anderson Cancer Center –
Technology Review Committee, $75,000
-
Lehman Brothers Foundation
award, $25,000 (Dr. Dickey)
-
“Living Legends” fund -
$200,000 (Dr. Dickey)
-
Culpeper award - $300,000
(Dr. Evans)
-
NCI Leukemia SPORE grant -
$50,000 (Dr. Evans)
-
SBIR, U01, and CLL foundation proposals pending,
~$3,000,000
|
|
